IVD Department qualitative test for the p24 antigen of HIV-1, HIV-1 (M, O) antibodies and/or HIV-2 antibodies - Vietnam Registration 2400227ĐKLH/BYT-HTTB
Access comprehensive regulatory information for IVD Department qualitative test for the p24 antigen of HIV-1, HIV-1 (M, O) antibodies and/or HIV-2 antibodies in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loại D medical device is registered under number 2400227ĐKLH/BYT-HTTB. The authorized representative in Vietnam is CÔNG TY TNHH THIẾT BỊ NHẬT ANH.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.
Device Details
Registration Details
2400227ĐKLH/BYT-HTTB
18006867/ĐKLH-BYT-TB-CT
Theo theo phụ lục
Theo phụ lục
Technical Details
LIAISON XL murex HIV Ab/Ag HT: The LIAISON XL murex HIV Ab/Ag HT test uses the CLIA (Chemiluminescent Immunoassay) technology to qualitatively determine the p24 antigen of the Human Immunodeficiency Virus type 1 (HIV-1) and quantitatively determine the specific antibodies against both types of HIV-1 (group M and group O) and/or type 2 (HIV-2) in human serum or plasma. The LIAISON XL murex HIV Ab/Ag HT test is used in the diagnosis of HIV-1/ HIV-2 infection and in the screening of blood or plasma donors. The test is performed only on the LIAISON XL automated immunoassay instrument. LIAISON XL murex Control HIV Ab/Ag HT: The LIAISON XL murex Control HIV Ab/Ag HT (negative and positive for HIV-1 antibodies and p24 antigen of HIV) is used in the CLIA (Chemiluminescent Immunoassay) LIAISON test to assess the reliability of test runs. The performance characteristics of the LIAISON XL murex Control HIV Ab/Ag HT have not been established for any other test or system other than the LIAISON XL automated immunoassay instrument.
Dates and Status
Feb 04, 2024

